AB
CASC

Amalgamated Bank’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Amalgamated Bank’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,763
Closed -$29K – 1294
2015
Q3 		$29K Sell
1,763
-1
-0.1% -$21 ﹤0.01% 1281
2015
Q2 		$40K Buy
+1,764
New +$27.9K ﹤0.01% 1335

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Amalgamated Bank's CASC Position: Q4 2015 in Review

Amalgamated Bank sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2015, closing a stake of 1,763 shares — an estimated $29K sold.

Amalgamated Bank first reported a position in CASC in Q2 2015 and held it in 2 quarters. The position peaked at $40K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

  • Amalgamated Bank reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Amalgamated Bank sold 1,763 Cascadian Therapeutics, Inc. shares in Q4 2015, an estimated $29K.
  • Amalgamated Bank first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
  • Amalgamated Bank's Cascadian Therapeutics, Inc. position peaked at $40K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on Amalgamated Bank's 13F filing for Q4 2015, filed 10 Feb 2016.